Literature DB >> 9717430

Cost-benefit analysis for the treatment of severe obesity.

L F Martin1, S White, W Lindstrom.   

Abstract

Cost-benefit and cost-effectiveness analyses (CEAs) are only now beginning to be used by business, government, and policymakers to evaluate various medical treatments. The evolution of why CEAs are being demanded is reviewed. To date, a formal CEA of obesity treatments has not been published. This article outlines how a CEA is performed, reviews data relevant to setting up a formal CEA of medical and surgical obesity treatments, and lists published reports that demonstrate the effectiveness of surgical obesity treatments. The general level of discrimination that society allows the obese to suffer also allows medical insurance companies, businesses, and government to not provide many obese Americans with obesity treatments that have established a level of effectiveness far surpassing many other forms of medical therapy. CEAs of obesity treatments, by themselves, cannot be expected to reverse this discrimination. This type of data, however, provides individual obese patients and their physicians with evidence to challenge policymakers' decisions, especially when cost-effective obesity treatments are excluded or placed at a lower priority than treatments with less proven effectiveness.

Entities:  

Mesh:

Year:  1998        PMID: 9717430     DOI: 10.1007/s002689900508

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  4 in total

Review 1.  Socioeconomic issues affecting the treatment of obesity in the new millennium.

Authors:  L F Martin; A Robinson; B J Moore
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

Review 2.  Biliopancreatic diversion in the surgical treatment of morbid obesity.

Authors:  Robrecht H G G Van Hee
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

3.  Associations between Obesity and Spinal Diseases: A Medical Expenditure Panel Study Analysis.

Authors:  Binwu Sheng; Chaoling Feng; Donglan Zhang; Hugh Spitler; Lu Shi
Journal:  Int J Environ Res Public Health       Date:  2017-02-13       Impact factor: 3.390

4.  Abnormal findings on routine upper GI series following laparoscopic Roux-en-Y gastric bypass.

Authors:  Raghav Raman; Bhargav Raman; Pavithra Raman; Stanford Rossiter; Myriam J Curet; Robert Mindelzun; John M Morton
Journal:  Obes Surg       Date:  2007-03       Impact factor: 3.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.